Figure 1.

Study design. (1) This study recruited pregnant women infected and/or vaccinated (n = 46) at various time points during gestation (first, second, and third trimesters and within 2 weeks prior to delivery), as well as those uninfected or vaccinated (controls, n = 11). (2) Maternal peripheral blood and fetal cord blood were collected at the time of birth. (3) Plasma was isolated and used for quantitative and functional SARS-CoV-2–specific antibody via enzyme-linked immunosorbent assay and cytokine/chemokine analysis via multiplex.